Another IGF-1R monoclonal antibody, dalotuzumab (MK-0646), known to cause IGF-1R degradation in tumor xenografts and to have comparable efficacy as the small molecule OSI-906 (linsitinib) [30], was analyzed in a phase I/II trial where it was combined with the EGFR inhibitor erlotinib in unselected NSCLC patients [31]. Here, EGFR is linked to neoplasm.